Take two of these in the morning, and I’ll know if you don’t

The FDA recently approved Otsuka Pharmaceutical’s Abilify MyCite for certain psychiatric conditions. No big whoop, other than it’s the first digital pill approved by the FDA. The pill has a sensor, called an Ingestible Event Marker (IEM) sensor, that wirelessly connects to a patch (developed by Proteus) worn on the torso, which gathers additional data before transmitting it to a phone app. So, what is the big whoop? You probably already got there but think “medication adherence.” According to this NIH paper, $100-$300 billion of avoidable health care costs have been attributed to nonadherence in the US annually, representing 3% to 10% of total US health care costs. Another angle, digital pills could become very “sticky” with patients and providers, potentially locking in revenue for pharma companies. Speaking of a “win-win” go here to get InsightCity’s first Buzzword Bingo card (it’ll be a collector’s item soon).